Search - tctmd.com

Displaying 661 - 680 of 1032

Sort: Relevancy | Date

Presentation TCT 2015

Tips and Tricks to Optimize Acute and Long-term BRS Outcomes

Presenter: Detlef G. Mathey, Nicolas M. Van Mieghem, Antonio Colombo

October 14, 2015

Presentation TCT 2015

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Presenter: Chuck Simonton, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

Imaging Insights Into BRS Failure Modes (Thrombosis and Restenosis)

Presenter: Detlef G. Mathey, Nicolas M. Van Mieghem, Yoshinobu Onuma

October 14, 2015

Presentation TCT 2015

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Presenter: Andrew Farb, Gregg W. Stone, John A. Spertus

October 14, 2015

Presentation TCT 2015

Neoatherosclerosis After BRS May Occur

Presenter: Detlef G. Mathey, Nicolas M. Van Mieghem, Corrado Tamburino

October 14, 2015

Presentation TCT 2015

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Presenter: Andrew Farb, Gregg W. Stone, Michael C. John

October 14, 2015

Presentation TCT 2015

Controversial Viewpoint: Characterizing BRS Class Effects BRS Designs Are More Different Than Alike (Regulatory Implications)

Presenter: Andrew Farb, Gregg W. Stone, Juan F. Granada

October 14, 2015

Presentation TCT 2015

Incidence and Predictors of BRS Scaffold Thrombosis

Presenter: Detlef G. Mathey, Nicolas M. Van Mieghem, Luis Ortega Paz, MD

October 14, 2015

Presentation TCT 2015

Assessing Whether Superiority Exists: Design, Rationale, and Status of ABSORB IV

Presenter: Stephen G. Ellis, Patrick W. Serruys, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (2-Year Outcomes): EVERBIO II

Presenter: Stephen G. Ellis, Patrick W. Serruys, Serban Puricel

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (2-Year Outcomes): ABSORB II (TCT First Report Investigation Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Bernard R. Chevalier

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): TROFI II

Presenter: Stephen G. Ellis, Patrick W. Serruys

October 14, 2015

Presentation TCT 2015

Featured Lecture: One-Year Patient-Level Pooled Meta-analysis From 4 ABSORB Trials in 3389 Randomized Patients

Presenter: Stephen G. Ellis, Patrick W. Serruys, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Dean J. Kereiakes

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Run-Lin Gao

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB Japan (ESC Late-Breaking Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Takeshi Kimura

October 14, 2015

Presentation TCT 2015

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Presenter: Stephen G. Ellis, Patrick W. Serruys, Davide Capodanno

October 14, 2015

Presentation TCT 2015

Featured Lecture: First Report of the 5-Year Cohort B Multimodality Imaging Results (And My Clinical Predictions Based on These Findings)

Presenter: Stephen G. Ellis, Patrick W. Serruys

October 14, 2015

Presentation TCT 2015

BRS Vasomotion and Microcirculatory Function Update

Presenter: Elazer R. Edelman, Juan F. Granada, Nick E. J. West

October 14, 2015

Presentation TCT 2015

Independent Bench Comparison of Different Bioresorbable Scaffolds

Presenter: Elazer R. Edelman, Juan F. Granada, John A. Ormiston

October 14, 2015

Advertisement

Tips and Tricks to Optimize Acute and Long-term BRS Outcomes

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Imaging Insights Into BRS Failure Modes (Thrombosis and Restenosis)

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Neoatherosclerosis After BRS May Occur

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Controversial Viewpoint: Characterizing BRS Class Effects BRS Designs Are More Different Than Alike (Regulatory Implications)

Incidence and Predictors of BRS Scaffold Thrombosis

Assessing Whether Superiority Exists: Design, Rationale, and Status of ABSORB IV

New Randomized Trial Data (2-Year Outcomes): EVERBIO II

New Randomized Trial Data (2-Year Outcomes): ABSORB II (TCT First Report Investigation Results and Beyond)

New Randomized Trial Data (1-Year Outcomes): TROFI II

Featured Lecture: One-Year Patient-Level Pooled Meta-analysis From 4 ABSORB Trials in 3389 Randomized Patients

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

New Randomized Trial Data (1-Year Outcomes): ABSORB Japan (ESC Late-Breaking Trial Results and Beyond)

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Featured Lecture: First Report of the 5-Year Cohort B Multimodality Imaging Results (And My Clinical Predictions Based on These Findings)

BRS Vasomotion and Microcirculatory Function Update

Independent Bench Comparison of Different Bioresorbable Scaffolds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content